Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986337 · 1 trial · 1 indication
PR interval is the time from the onset of the P wave to the start of the QRS complex
QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization
QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave.
The QT interval is the time from the start of the Q wave to the end of the T wave.
| Arm | Type | Description |
|---|---|---|
| Part A Single Ascending Dose (SAD) Cohort A1 | EXPERIMENTAL | - |
| Part A SAD Cohort A2 | EXPERIMENTAL | - |
| Part A SAD Cohort A3 | EXPERIMENTAL | - |
| Part A SAD Cohort A4 | EXPERIMENTAL | - |
| Part A SAD Cohort A5 | EXPERIMENTAL | - |
| Part A SAD Cohort A6 | EXPERIMENTAL | - |
| Part B Multiple Ascending Dose (MAD) Cohort B1 | EXPERIMENTAL | - |
| Part B MAD Cohort B2 | EXPERIMENTAL | - |
| Part B MAD Cohort B3 | EXPERIMENTAL | - |
| Part B MAD Cohort B4 | EXPERIMENTAL | - |
| Part C MAD in Japanese Healthy participants Cohort C1 | EXPERIMENTAL | - |
| Part C MAD in Japanese Healthy participants Cohort C2 | EXPERIMENTAL | - |
| Part C MAD in Japanese Healthy participants Cohort C3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986337 | DRUG | Specified Dose on Specified Days |
| BMS-986337 Placebo | OTHER | Specified Dose on Specified Days |
| Famotidine | BIOLOGICAL | Specified Dose on Specified Days |
Inclusion Criteria: * No clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations * For Japanese cohorts in Part C, must be first-generation Japanese (born in Japan, not living outside of Japan for more ...
BMS-986337 is an investigational small molecule being studied in healthy volunteers. It is being evaluated for safety, tolerability, and drug levels when taken by mouth. The drug is not approved for any condition and is in early clinical development.
BMS-986337 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy participants.
BMS-986337 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing.
BMS-986337 has one completed Phase 1 clinical trial, identified as NCT04550195. The study evaluated the safety, tolerability, and drug levels of BMS-986337 when taken by mouth by healthy participants. The trial was conducted in the Netherlands with 26 participants aged 21 years and older.
BMS-986337 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial focused on safety and tolerability in healthy volunteers, and the drug has not yet progressed to later-stage trials or regulatory review.